Receive our newsletter – data, insights and analysis delivered to you
July 9, 2009

Amarin Reaches Special Trials Agreement With FDA

Amarin has reached an agreement with the US Food and Drug Administration under a special protocol assessment (SPA), to go ahead with the planned phase-III clinical trial of AMR101 (ethyl-EPA) for patients with mixed dyslipidemia. This is the second SPA agreement received by Amarin for AM

By cms admin

Amarin has reached an agreement with the US Food and Drug Administration under a special protocol assessment (SPA), to go ahead with the planned phase-III clinical trial of AMR101 (ethyl-EPA) for patients with mixed dyslipidemia.

This is the second SPA agreement received by Amarin for AMR101 in cardiovascular disease and follows the SPA agreement obtained in May 2009 in relation to the planned registration trial with AMR101 in patients with very high triglycerides.

Amarin chairman and CEO Thomas Lynch said that receiving FDA agreement on the phase-III trial in mixed dyslipidemia was an important endorsement of the company’s strategy, which aims to provide a more comprehensive label for AMR101.

“We plan to commence both this mixed dyslipidemia trial and the MARINE study in the third quarter of 2009, pending completion of the company’s longer term funding,” Lynch said.

The phase-III mixed dyslipidemia trial will consist of a multi-centre, placebo-controlled, randomised, double-blind, 12-week study.

The trial will evaluate the efficacy and safety of 2g and 4g of AMR101 in patients with high triglyceride levels of =200mg/dL and <500mg/dL who are on statin therapy. The primary endpoint in the trial is to record a percentage change in triglyceride level from baseline to week 12.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU